Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05751733 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 2, 2023 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The goal of this Mesylate apatinib versus standard second-line TKI in the treatment of advanced gastrointestinal stromal tumors: a randomized, open, controlled, single-center clinical study is to explore the efficacy and safety of Apatinib compared with second-line treatment in advanced GIST patients with first-line TKI failure. The main questions it aims to answer are: * To explore the efficacy and safety of Apatinib compared with standard second-line treatment for GIST with advanced first-line TKI failure. * To explore the expression level and MVD value of VEGFR2 in GIST, and to explore the relationship between the expression level and the location, size, mitotic image and recurrence risk grading of GIST. Patients with advanced GIST were randomly included in the trial group and the control group at a ratio of 1:1.
Trial Details
NCT Number NCT05751733
Lead Sponsor Xiangya Hospital of Central South University
Collaborators: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions
(from sponsor)		 Gastrointestinal Stromal Tumors
Related terms Gastrointestinal Stromal Tumors
Enrollment 258 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov